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Emerging evidence suggests that antibodies against merozoite proteins involved in
Plasmodium falciparum invasion into the red blood cell (RBC) play an important role in
clinical immunity to malaria. The protein family of parasite antigens known as P. falciparum
reticulocyte binding protein-like homolog (PfRh) is required for RBC invasion. PfRh5 is the
only member within the PfRh family that cannot be genetically deleted, suggesting it plays
an essential role in parasite survival. This antigen forms a complex with the cysteine-rich P.
falciparum Rh5 interacting protein (PfRipr), on the merozoite surface during RBC invasion.
The PfRh5 ectodomain sequence and a C-terminal fragment of PfRipr were cloned and
expressed in Escherichia coli and baculovirus-infected cells, respectively. Immunization
of rabbits with these recombinant proteins induced antibodies able to inhibit growth of
various P. falciparum strains. Antibody responses to these proteins were investigated in a
treatment–re-infection study conducted in an endemic area of Papua New Guinea (PNG) to
determine their contribution to naturally acquired immunity. Antibody titers to PfRh5 but not
PfRipr showed strong association with protection against P. falciparum clinical episodes.
When associations with time-to-ﬁrst infection were analyzed, high antibody levels against
PfRh5 were also found to be associated with protection from high-density infections but
not from re-infection. Together these results indicate that PfRh5 is an important target of
protective immunity and constitutes a promising vaccine candidate.
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INTRODUCTION
Malaria is one of the most serious infectious diseases of humans
causing 500 million clinical cases annually, with nearly 25% of
the global burden occurring in the Asia-Paciﬁc. The blood stage
of the Plasmodium parasite is entirely responsible for malaria-
associated pathology (Miller et al., 2002). Fatalities are associated
with a spectrum of disease syndromes including acute respira-
tory distress, hypoglycemia, renal failure, pulmonary oedema and
cerebral involvement. The most susceptible population to severe
malaria are children under the age of 5, who have experienced
few parasitic infections. After years of repeated exposure, indi-
viduals living in endemic areas develop clinical immunity. This
form of protection does not result in sterilizing immunity but pre-
vents clinical episodes by signiﬁcantly reducing parasite burden.
Naturally acquired immunity predominantly targets blood-stage
parasites and appears to require antibody responses since passive
transfer of sera from clinically immune individuals protects non-
immune recipients from high parasitemia and disease symptoms
(Cohen et al., 1961).
During blood-stage replication, Plasmodium falciparum mero-
zoites invade erythrocytes through a complex multistep process
that requires initial contact of the parasite with the red blood
cell (RBC) surface followed by apical reorientation of the mero-
zoite, tight junction formation and ﬁnal entry into the erythrocyte
(reviewed in Cowman and Crabb, 2006). These invasion steps
dependon interactions between speciﬁc parasite proteins and their
receptors on the erythrocyte surface. Two families of invasion lig-
ands have been identiﬁed in P. falciparum: the erythrocyte-binding
antigens (EBAs) and the P. falciparurm reticulocyte binding
protein-like homologs (PfRhs; reviewed in Cowman and Crabb,
2006). EBAs are orthologs of the Duffy-binding protein of P. vivax
and include EBA-140, EBA-175, and EBA-181. They consist of an
N-terminal cysteine-rich domain, a highly conserved domain, a
C-terminal cysteine-rich domain and a transmembrane and cyto-
plasmic domain (reviewed in Cowman and Crabb, 2006). EBAs
are located in the micronemes and are secreted onto the parasite
surface just before invasion. Whereas EBA-175 has been shown
to interact with glycophorin A on the surface of the erythrocyte
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(ref), EBA-140 binds to glycophorin C (Maier et al., 2009). The
receptor for EBA-181 has not been identiﬁed. The PfRhs family
consists of ﬁve proteins located in the parasite’s rhoptries. Mem-
bers of this family include: PfRh1, PfRh2a, PfRh2b, PfRh4, and
PfRh5. So far only the host receptor for PfRh4 (Tham et al., 2010;
complement receptor 1) and PfRh5 (Crosnier et al., 2011; basi-
gin) have been identiﬁed. Except for PfRh5 (Baum et al., 2009), all
the other members of this family are large type-1 transmembrane
proteins.
PfRh5 is considerably smaller than the other PfRh proteins
and lacks a transmembrane domain (Baum et al., 2009). After its
release from the rhoptries, PfRh5 forms a complex with a cysteine-
rich antigen named P. falciparumRh5 interacting protein (PfRipr),
which facilitates its expression on the merozoite’s surface for ery-
throcyte invasion (Chen et al., 2011). The genes encoding both
PfRh5 and PfRipr are refractory to gene targeted deletion, sug-
gesting essential roles for these antigens in parasite invasion (Baum
et al., 2009; Chen et al., 2011).
P. falciparum invasion ligands are targets of inhibitory anti-
bodies that prevent parasite invasion and subsequent replication
in the erythrocyte (reviewed in Cowman and Crabb, 2006). Thus
these molecules have been proposed as vaccine candidates. With
this in view, PfRh5 has recently received considerable attention,
since unlike many other merozoite antigens, it has limited genetic
diversity among P. falciparum isolates (Bustamante et al., 2013).
Moreover, rabbit antisera raised against PfRh5 have been shown
to inhibit parasite replication in vitro (Baum et al., 2009; Dou-
glas et al., 2011). Parasite growth inhibition was observed across
a wide range of laboratory-adapted parasite lines, suggesting that
PfRh5 could be an effective vaccine target (Bustamante et al., 2013;
Douglas et al., 2014; Reddy et al., 2014). Similarly, antibodies to
PfRipr have been shown to inhibit parasite growth in vitro (Chen
et al., 2011).
To date, it is unclear whether PfRipr is recognized by naturally
acquired antibodies from individuals residing in malaria-endemic
areas. Moreover, despite promising results in experimental animals
and in vitro assays on the potential for PfRh5 as a leading vaccine
candidate, there are conﬂicting reports on whether this antigen is
the target of naturally acquired immunity, with studies suggesting
suggesting that PfRh5 has poor natural immunogenicity (Douglas
et al., 2011) or that anti-PfRh5 responses predict protection from
clinicalmalaria (Tran et al., 2014). To further address this question,
we have expressed stable, soluble forms of PfRh5 and PfRipr. The
association between antibody responses to the PfRh5 and PfRipr
recombinant proteins with reduced risk to re-infection and symp-
tomatic disease was investigated in a treatment–reinfection study
in a malaria-endemic area. Our main results indicate that in a
population of children who are actively acquiring immunity to
malaria, anti-PfRh5 antibody responses are associated with pro-
tection against P. falciparum clinical episodes and high-density
infections.
MATERIALS AND METHODS
STUDY POPULATION AND ETHICS STATEMENT
Plasma samples were obtained from a prospective treatment–
reinfection study of 206 children aged from5 to 14 years conducted
in Madang province of Papua New Guinea (PNG). Full details
of this cohort have been previously described (Michon et al.,
2007). Brieﬂy, venous blood was collected at study enrolment
into heparinized tubes and plasma was stored at −80◦C. All
participants received a 7-day treatment of oral artesunate to
clear existing infections. During a 6-month follow up period,
participants were monitored every two weeks for symptomatic
illness and/or parasitemia (active surveillance) and when a child
presented with symptoms at the local Mugil Health Centre (pas-
sive surveillance). Re-infection was detected by post-PCR ligase
detection reaction–ﬂuorescent microsphere assay (LDR-FMA)
and light microscopy (LM) on Giemsa stained blood smears.
Re-infections were categorized to (1) PCR-detectable, (2) LM-
detectable, (3) LM-detectable re-infection with >500 parasites
per μl, and (4) LM-detectable re-infection with >5000 para-
sites per μl. Clinical episode was deﬁned as the presence of
fever with ≥37.5◦C and >5000 parasites/μl. The study was
approved by the Medical Research Advisory Committee (MRAC),
PNG Ministry of Health, The Walter and Eliza Hall Institute
Human Research Ethics Committee and the institutional review
board of the Veteran’s Affairs Medical Center (Cleveland, OH,
USA).Written consent was obtained from parents/guardians of all
participants.
EXPRESSION OF RECOMBINANT PROTEINS AND ANTIBODY
GENERATION
The PfRh5 ectodomain sequence was codon-optimized for
Escherichia coli expression and cloned into the pET-303 vector
(Invitrogen, MA, USA). The C-terminally HIS tagged expres-
sion product was refolded from the insoluble pellet material
under standard conditions. PfRipr (AA604-1086) was cloned
into pTri-Ex 2 vector for expression in baculovirus-infected
Hi-5 cells (Life Technologies, MA, USA). HIS-FLAG tagged
PfRiPr protein was puriﬁed from the cell culture supernatant
by incubation with M2-FLAG beads (Sigma, MO, USA), fol-
lowed by elution with FLAG peptide in NaCl-Tris buffer pH
8.0. The peptide was removed by dialysis prior to immu-
nization. Purity and integrity of recombinant proteins were
assessed in SDS–polyacrylamide gels (Invitrogen, MA, USA).
Rabbits were immunized twice with 100 μg PfRh5 in GLA-
SE adjuvant (a kind gift from Darrick Carter, IDRI), or three
times with 200 μg PfRipr in Freund’s adjuvant. Total IgG
was puriﬁed from immune sera as described (Healer et al.,
2013). All experiments were performed in compliance with
the Walter and Eliza Hall Institute Animal Ethics Committee
requirements.
GROWTH INHIBITION ASSAYS
Growth inhibition assays (GIA) using IgG isolated from immu-
nized rabbits were performed as described (Healer et al., 2013).
Brieﬂy, serial dilutions of puriﬁed IgG starting at 2 mg/ml
were added to P. falciparum-infected RBC (3D7, W2mef, and
FCR3) at a parasitemia of 0.5%. Parasitemia was counted
after 48 h and speciﬁc growth inhibition calculated relative to
parasites grown in non-immune IgG. Speciﬁc growth inhibi-
tion was calculated relative to parasites grown in non-immune
IgG.
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ELISA
Microtiter plates were coated with recombinant PfRh5 (2 μg/ml)
and PfRipr (0.5 μg/ml) in carbonate buffer pH 9.6 by overnight
incubation at 4◦C. Empty sites were blocked with 5% skim milk
for 1 h at 37◦C.After washingwith 0.05%Tween-PBS, 100μl of 1:2
serially diluted plasma samples were added to plates and incubated
at 37◦C for 1 h. The plates were washed three times and incu-
bated with a peroxidase-conjugated mouse anti-human antibody
(Southern Biotech, AL, USA). Bound complexes were detected by
reaction with tetramethy-benzidine (KBL, MD, USA) and H2O2.
Absorbance was read at 450 nm. Plasma samples from malaria
naïve anonymous Australian blood donors were included as nega-
tive controls. Antibody titerswere calculated as the plasmadilution
with an optical density (OD) value higher than that observed for
negative controls at a 1/100 dilution.
STATISTICAL ANALYSES
Statistical analysis was performed using STATA 9.2 (STATA-Corp.,
College Station, TX, USA). For analysis of associations with clin-
ical outcomes, participants with no detectable parasitemia by
PCR or LM during follow up were regarded as non-exposed and
excluded from the analysis. Demographic and clinical variables
were assessed as potential confounders. Kaplan–Meiermethod and
log-rank test were used to explore associations between antibody
titers and time to P. falciparum re-infection or clinical episodes.
Cox proportional hazards modeling was used to calculate hazard
ratios (HR) for time-to-ﬁrst P. falciparum infection by PCR, LM,
and time-to-ﬁrst infection of>500 and>5000 parasites/μL. Pois-
son model was used to obtain incidence rate ratio (IRR) for the
incidence of clinicalmalaria episodes throughout the study period.
HR and IRR were adjusted for identiﬁed confounders. Differences
in antibody titers between categorical variables were assessed using
Wilcoxon rank sum test or Kruskal–Wallis tests.
RESULTS
RECOMBINANT PfRh5 AND PfRipr ARE IMMUNOGENIC AND INDUCE
PARASITE GROWTH INHIBITORY ANTIBODIES
The PfRh5 ecotodomain sequence and the C-terminal PfRipr
fragment from 3D7 were cloned and expressed in E. coli and
baculovirus-infected insect cells, respectively. HIS-FLAG tagged
proteins were puriﬁed with M2-FLAG beads. SDS-PAGE analysis
of the puriﬁed recombinant proteins revealed highly pure protein
preparations with predominant bands at 63 kDa corresponding to
PfRh5 and 65 kDa corresponding to PfRipr (Figure 1A).
To determine if the recombinant proteins were immunogenic,
rabbits were immunized twice with 100 μg PfRh5 in GLA-SE
adjuvant or three times with 200 μg PfRiPr in Freund’s adjuvant.
Seroconversion of immunized rabbits was successfully conﬁrmed
by ELISA using PfRh5 and PfRipr recombinant proteins (data not
shown). Total IgG was puriﬁed from immune sera 2 weeks after
the last immunization and added to P. falciparum trophozoite
cultures to determine their capacity to inhibit parasite growth.
Figures 1B,C shows that both anti-PfRh5 and anti-PfRipr anti-
bodies inhibit growth of P. falciparum 3D7, W2Mef, and FCR3 in
a dose dependent manner. Incubation with 2 mg/ml of both anti-
bodies resulted in∼40%of growth inhibition of all parasite strains
tested. Thus immunization with these novel recombinant proteins
induces antibodies that prevent growth of multiple P. falciparum
clones.
ANTI-PfRh5 ANTIBODIES ARE ASSOCIATED WITH PROTECTION FROM
HIGH PARASITEMIA AND REDUCE INCIDENCE OF MALARIA CLINICAL
EPISODES
A preliminary screen conducted in the Madang Province of PNG
suggested that antibodies to PfRh5 and to the EGF-like domain
of PfRipr show an intermediate association with protection from
clinical malaria (Richards et al., 2013). To further explore this
hypothesis, antibody titers to the recombinant PfRh5 and PfRipr
proteins described above, were measured by ELISA in a lon-
gitudinal cohort of PNG children. Similar to other endpoints
previously examined in this cohort (Michon et al., 2007; Richards
et al., 2010; Hill et al., 2013), antibody responses to PfRh5 were
heterogeneous and thus divided into terciles for analysis. The
relationship between antibody levels amongst low (L), medium
(M), and high (H) responders and time-to-reinfection of differ-
ent parasite densities was investigated in Kaplan–Meier survival
curves and a log-rank test was used to determine the differ-
ence between groups. Figure 2 shows that anti-PfRh5 responses
protected from high-density (≥5000 parasites/μL) parasitemia
(H vs L: p < 0.0001, M vs L: p = 0.019) but not against
re-infection per se (assessed by PCR or LM). The association
between antibody titers and the risk of acquiring new P. falci-
parum infections was also analyzed by Cox regression model. In
agreement with previous studies with this cohort (Michon et al.,
2007; Richards et al., 2010; Hill et al., 2013), age (<9 years and
≥9 years) and location of residencewere identiﬁed as confounders.
Thus HRs were adjusted for those variables. Anti-PfRh5 antibody
responses did not reduce the risk of P. falciparum re-infection
by PCR, LM or moderate density infection (>500 parasites/μL).
However, a reduced risk of developing a high-density infec-
tion (>5000 parasites/μL) was observed for high anti-PfRh5
titers, even after adjustment for age and location of participants
(Table 1).
The association of anti-PfRh5 antibody responses with time-
to-ﬁrst clinical episode was also determined. Anti-PfRh5 antibody
levels were found to be signiﬁcantly associated with a protection
from clinical malaria, as medium and high antibody responders
showed 61.7 and 82.2% reduced risk of experiencing a clinical
episode than low responders after the adjustment for confounders
(M vs L: adjusted HR = 0.383, 95% CI = 0.216–0.678, p = 0.001;
H vs L: adjusted HR = 0.178, 95% CI = 0.082–0.389, p < 0.001;
Table 2). A Poisson regression was used to test for associations
between antibody levels and overall incidence of clinical disease.
Increased anti-PfRh5 antibody responseswere found tobe strongly
associated with reduced incidence of malaria clinical episode dur-
ing the 6 month follow-up period (M vs L: adjusted IRR = 0.539,
95% CI = 0.344–0.842, p = 0.007; H vs L: adjusted IRR = 0.257,
95% CI = 0.134–0.492, p< 0.001; Table 3). Moreover, anti-PfRh5
antibody titers were found to be signiﬁcantly higher in individuals
that did not experience clinical episodes compared to those that
experienced 1, 2, or 3 malaria clinical episodes over the follow up
period (Figure 3). Thus together these results indicate that natu-
rally acquired anit-PfRh5 antibodies protect from parasitemia of
high density and clinical illness.
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FIGURE 1 | Immunization of rabbits with recombinant PfRh5 and PfRip5
induces strain-transcending parasite growth inhibitory antibodies.The
PfRh5 ectodomain sequence and the C-terminal PfRipr fragment were cloned
and expressed in E. coli and baculovirus-infected Hi-5 cells, respectively.
SDS-PAGE analysis (A) of the puriﬁed recombinant proteins. Total IgG puriﬁed
from sera of PfRh5 (B) and PfRipr (C) immunized rabbits was added to P.
falciparum 3D7,W2Mef, and FCR3 cultures to determine their capacity to
inhibit parasite growth.
FIGURE 2 | Probability of remaining free of malaria re-infection
amongst individuals with different anti-PfRh5 antibody levels.
Time-to-ﬁrst PCR-positive P. falciparum blood-stage infection (A),
LM-positive (B), LM-positive with ≥500 parasites/μL (C) and LM-positive
with ≥5000 parasites/μl (D) in individuals with low, medium or high
anti-PfRH5-speciﬁc antibody titers at study enrolment, as determined by
Kaplan–Meier survival analysis. Log-rank was used to determine differences
among responder groups, p < 0.0001 between high and low responders
and p = 0.019 between medium and low responders with
LM ≥ 5000 parasites/μl.
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Table 1 | Associations between anti-PfRh5 antibody titers and risk of acquiring P. falciparum infections of varying density.
Anti-PfRh5 responses
Medium vs low High vs low
HR 95% CI P HR 95% CI P
PCR Unadjusted 0.95 (0.66–1.35) 0.76 0.88 (0.61–1.27) 0.51
PCR Adjusted 0.98 (0.68–1.42) 0.93 0.87 (0.57–1.33) 0.53
LM Unadjusted 0.99 (0.68–1.45) 0.96 0.89 (0.61–1.31) 0.56
LM Adjusted 1.10 (0.74–1.64) 0.64 1.05 (0.67–1.65) 0.83
LM500 Unadjusted 0.87 (0.58–1.30) 0.49 0.63 (0.41–0.97) 0.03
LM500 Adjusted 1.00 (0.64–1.54) 0.99 0.85 (0.51–1.42) 0.55
LM5000 Unadjusted 0.56 (0.34–0.93) 0.03 0.27 (0.15–0.50) <0.001
LM5000 Adjusted 0.61 (0.36–1.05) 0.07 0.37 (0.18–0.72) <0.001
Hazard ratio (HRs) were determined to assess associations with anti-PhRh5 antibody responses and time-to-ﬁrst PCR detectable, LM detectable, ≥500 parasites/μl,
and ≥5000 parasites/μl P. falciparum infections. HRs were adjusted for age and location of participants. Signiﬁcant associations are shown in bold.
Table 2 | Association between IgG responses to PfRh5 and PfRipr and time-to-first clinical episode.
PfRh5 PfRipr
M vs L H vs L M vs L H vs L
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Unadjusted 0.45 (0.26–0.77) <0.01 0.17 (0.08–0.35) <0.01 0.90 (0.51–1.60) 0.73 0.55 (0.30–1.00) 0.053
Adjusted 0.38 (0.22–0.68) <0.01 0.18 (0.08–0.39) <0.01 0.90 (0.50–1.61) 0.72 0.64 (0.35–1.17) 0.150
Hazard ratios (HRs) were determined to assess associations with anti-PhRh5 and anti-PfRipr antibody responses and time to P. falciparum clinical episodes with
≥5000 parasites/μl. Values represent unadjusted and adjusted ratios (age and location) ±95% conﬁdence intervals (CI). Signiﬁcant associations are shown in bold.
Table 3 | Association between IgG responses to PfRh5 and PfRipr and incidence of malaria clinical episodes.
PfRh5 PfRipr
M vs L H vs L M vs L H vs L
IRR 95% CI P IRR 95% CI P IRR 95% CI P IRR 95% CI P
Unadjusted 0.55 (0.35–0.85) <0.01 0.21 (0.12–0.39) <0.01 1.03 (0.64–1.65) 0.90 0.81 (0.49–1.33) 0.41
Adjusted 0.54 (0.34–0.84) <0.01 0.26 (0.13–0.49) <0.01 1.05 (0.65–1.69) 0.83 0.87 (0.53–1.44) 0.58
Incidence rate ratios (IRR) were determined to assess associations between antibody responses and overall incidence of clinical episodes for all individuals. Values
represent unadjusted and adjusted ratios (age and location) ± 95% conﬁdence intervals (CI). Signiﬁcant associations are shown in bold.
ANTI-PfRipr ANTIBODIES ARE NOT ASSOCIATED WITH REDUCED RISK
OF P. falciparum RE-INFECTION AND SYMPTOMATIC MALARIA
The relationship between anti-PfRipr antibody titers and time
to reinfection of different parasite densities was investigated
in Kaplan–Meier survival curves and a log-rank test was used
to determine the difference between high, medium and low
responders. Figure 4 shows that only high responders (H vs L:
p = 0.01) appeared to be protected from parasitemia of high
density (>5000 parasites/μl) but not from moderate-density par-
asitemia (>500 parasites/μl) or re-infection. Before adjustment
for confounders, high responders showed a reduced risk to
develop a high-density infection (H vs L, HR: 0.49, 95% CI
0.28–0.86, p = 0.02). However, this association did not reach
statistical signiﬁcance after adjustment for age and location of
the study participants (H vs L, HR: 0.38, 95% CI 0.33–1.05,
p = 0.07).
The association of anti-PfRipr antibody levels with risk of expe-
riencing a malaria clinical episode was also determined. The risk
of developing clinical episodes (Table 2) as well as the overall
incidence of malaria episodes throughout the 6 month follow-up
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FIGURE 3 | High anti-PfRh5 antibody levels in individuals protected
from clinical malaria. Anti-PfRh5 antibody titers were stratiﬁed on the
basis of the number of clinical episodes during the 6 month follow-up
period. Statistical signiﬁcance was determined by Kruskal–Wallis test and
byWilcoxon rank sum test (*p < 0.01, **p < 0.001).
period (Table 3) were similar amongst all responders, suggesting
anti-PfRipr antibodies do not play an important role in clinical
outcome.
DISCUSSION
Antibodies that prevent P. falciparum invasion into erythrocytes
are an important effector mechanism mediating immunity against
blood-stage malaria parasites. Over the past 10 years, a large body
of data has been generated towards understanding the molecu-
lar basis of merozoite invasion into the erythrocyte and many
parasite antigens have been characterized. From those antigens,
PfRh5 has been identiﬁed as an attractive vaccine candidate since
it appears to be essential for parasite survival (Baum et al., 2009),
has limited sequence polymorphisms andupon animal immuniza-
tion induces broadly growth inhibitory antibodies (Douglas et al.,
2011; Bustamante et al., 2013; Reddy et al., 2014). Consistent with
those ﬁndings, immunization of rabbits with the PfRh5 recom-
binant protein described here induced strong antibody responses
able to inhibit parasite growth across three different P. falciparum
lines.
Previous studies suggested that PfRh5 is not highly immuno-
genic in humans exposed to malaria (Douglas et al., 2011) and that
antibody responses to this antigen are rapidly lost at the endof high
transmission season. However, a recent study conducted in Mali
reported that naturally acquired anti-PfRh5 antibody responses
predict protection from clinical malaria (Tran et al., 2014). Con-
sistent with those ﬁndings, our study revealed strong associations
between anti-PfRh5 antibody titers and protection from symp-
tomaticmalaria andhigh-density parasitemia but not re-infection.
Moreover, anti-PfRh5 antibodies at study baseline were found to
FIGURE 4 | Probability of remaining free of malaria re-infection
amongst individuals with different anti-PfRipr antibody levels.
Time-to-ﬁrst PCR-positive P. falciparum blood-stage infection
(A), LM-positive (B), LM-positive with ≥500 parasites/μL (C) and
LM-positive with ≥5000 parasites/μl (D) in individuals with low,
medium, or high anti-PfRipr-speciﬁc antibody titers at study
enrolment, as determined by Kaplan–Meier survival analysis. Log-rank
was used to determine differences among responder groups,
p = 0.01 between high and low responders with ≥5000
parasites/μl.
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reduce the overall incidence of clinical episodes throughout the
6-month follow-up period.
PfRh5 exists in a membrane-associated complex with the
cysteine-rich protein PfRipr. We have previously found antibod-
ies to E. coli expressed C-terminal and N-terminal fragments of
PfRipr inhibit merozoite attachment to the erythrocytes as well
as in vitro parasite growth (Chen et al., 2011). Here immuniza-
tion of rabbits with a baculovirus-expressed C-terminal fragment
of PfRipr induced strong antibody responses, able to inhibit
the in vitro growth of several P. falciparum lines to a simi-
lar level than that observed for anti-PfRh5 rabbit antibodies.
Recombinant PfRipr was readily recognized by plasma from PNG
participants in our cohort study. However, unlike anti-PfRh5
responses, antibodies against PfRipr showed only a modest asso-
ciation with protection from high-density parasitemia, which
did not reach statistical signiﬁcance after adjustment for con-
founder variables. Interestingly, despite the close association of
PfRipr and PfRh5 on the surface of the merozoite, antibody
responses against the two antigens appeared to be only weakly cor-
related (data not shown). To date, antibody responses to PfRipr
have not been extensively investigated. Further work in other
settings is required to determine whether this Plasmodium anti-
gen is an important target of naturally acquired immunity to
malaria.
There is an urgent need for a blood stage component in an
anti-malarial vaccine to reduce parasite burdens responsible for
morbidity and mortality in susceptible individuals. Development
of a blood stage vaccine against malaria has been largely delayed
mainly due to the high level of polymorphism in the few anti-
genic targets that were tested in clinical trials (Lyon et al., 2008;
Ogutu et al., 2009). Thus it has been suggested that an effective
blood stage vaccine should include more than one (preferably
conserved) antigenic components to circumvent parasite phe-
notypic diversity. This report and others (Douglas et al., 2011;
Bustamante et al., 2013; Reddy et al., 2014) demonstrated that
immunization with PfRh5 results in the induction of strain-
transcending parasite growth inhibitory antibodies. Similarly,
we have recently found that immunization of rabbits with a
highly conserved region of EBA-175 (region III–V) also induces
potent, parasite strain-transcending growth inhibitory antibod-
ies, which appear to be active at concentrations even lower
than those described for anti-PfRh5 antibodies (Healer et al.,
2013). Further studies are now required to investigate whether
co-immunization with PfRh5 and the III–V EBA-175 region
results in synergistic interactions and induces robust antibody
responses required for the development of an effective malaria
vaccine.
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